Core Insights - ABL Bio and GSK have entered into a multi-program agreement to develop novel medicines targeting neurodegenerative diseases using ABL Bio's Grabody-B platform technology, which facilitates drug delivery across the blood-brain barrier [1][2][3] - ABL Bio is set to receive up to £77 million in upfront and near-term payments, with potential total payments reaching £2.075 billion across various programs [3] Company Overview - ABL Bio is a clinical-stage biotech company focused on bispecific antibody technology for immuno-oncology and neurodegenerative diseases, with multiple clinical projects underway across different countries [5] - The company is developing several pipelines, including ABL301, ABL001 (tovecimig), ABL111 (givastomig), and others, with ABL001 having received Fast Track designation from the FDA [5] Industry Context - The blood-brain barrier (BBB) presents a significant challenge in developing treatments for neurological diseases, and ABL Bio's Grabody-B technology aims to overcome this limitation by targeting the Insulin-like Growth Factor 1 Receptor (IGF1R) [2] - There is a growing need for new therapeutics for neurodegenerative diseases, driven by an aging population and the increasing prevalence of conditions such as Alzheimer's and Parkinson's [4]
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases